A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.

Trial Details

NCT ID
NCT05150691
Phase
PHASE1 / PHASE2
Sponsor
DualityBio Inc.
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • DB-1303/BNT323
  • Pertuzumab Injection
  • Ritonavir
  • Itraconazole
Locations (sample)
  • Cerritos, California, United States|33.85835,-118.06479
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Coral Springs, Florida, United States|26.27119,-80.2706
  • Miami, Florida, United States|25.77427,-80.19366
  • Newnan, Georgia, United States|33.38067,-84.79966

Key Eligibility Criteria

  • Has a pathologically documented HER2-positive or HER2-expressing (except for cohort 2h where the requirement is HER2-null), advanced/unresectable, …
  • At least 1 measurable lesion (per RECIST 1.1)
  • Provide signed informed consent
  • ECOG performance status (PS) of 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →